BIOCARTIS GROUP NV

BCART
Real-time Quote. Real-time  - 01/26 11:35:24 am
4.6EUR +0.88%
Business Summary
Healthcare
Healthcare Services
 Healthcare Equipment & Supplies
  Medical Equipment, Supplies & Distribution
   Medical Equipment
Biocartis Group NV specializes in the development of molecular diagnostic systems. Especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.
Net sales by source of income are mainly distributed between products sales (64.7%) and sale of collaboration services (33.3%; especially research and development services).

Number of employees : 462 people.
Sales per Business
20182019
EUR
(in Million)
%EUR
(in Million)
%
Cartridge 14.6652.7% 18.0048.1%
Research & Development Services 4.3415.6% 9.0324.1%
Idylla System 2.408.6% 4.2311.3%
License Fees 3.1611.4% 2.526.7%
Idylla System Rental 1.786.4% 1.995.3%
Milestone 0.8333% 0.9082.4%
Idylla System Service 0.6392.3% 0.7692.1%
Sales per region
2019
EUR
(in Million)
%
United States 14.7539.4%
Rest of the World 13.8537%
China 3.088.2%
Spain 2.817.5%
France 2.205.9%
Belgium 0.7562%
Managers
Name Title
Herman Verrelst Chief Executive Officer & Executive Director
Christian Reinaudo Independent Chairman
Piet Houwen Chief Operating Officer
Jean-Marc Roelandt Chief Financial Officer
Benoit Devogelaere Chief Technology Officer
Roald Borré Non-Executive Director
Ann-Christine Sundell Independent Director
Luc Gijsens Independent Director
Christine D. Kuslich Independent Director
Erwin Sablon Head-Research & Development, Alliance Management
Shareholders
Name Equities %
Invesco Advisers, Inc. 9,924,453 17.2%
Johnson & Johnson Innovation JJDC, Inc. 5,481,128 9.52%
Participatiemaatschappij Vlaanderen NV 2,362,610 4.11%
Credit Suisse Asset Management (Schweiz) AG 2,026,714 3.52%
Sycomore Asset Management SA 1,684,620 2.93%
Debiopharm Innovation Fund /Management/ 1,662,963 2.89%
Mirova SA (Investment Management) 1,073,965 1.87%
Threadneedle Asset Management Ltd. 710,018 1.23%
KBC Asset Management NV 581,127 1.01%
Metzler Asset Management GmbH 576,000 1.00%
Company contact information
Generaal De Wittelaan 11 B
BE-2800 Mechelen, Antwerpen


Phone : +32 15 632 600
Fax :
web site : https://investors.biocartis.com/en
Markets and indexes
-
- Compartiment B
- BEL Mid / PEA
Stock Exchange Codes
- ISIN Code :  BE0974281132
- Bloomberg Code :  BCART:BE
- Reuters Code :  BCART.BR
Sector Medical Equipment
1st jan.Capi. (M$)
BIOCARTIS GROUP NV-1.08%318
NOVOCURE LIMITED-3.38%17 019
MASIMO CORPORATION-4.21%14 154
PENUMBRA, INC.46.25%9 293
ASAHI INTECC CO., LTD.-8.23%8 680
GETINGE AB3.36%6 502
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.5.53%4 606
SHOCKWAVE MEDICAL, INC.23.36%4 384
SI-BONE, INC.7.69%1 042
SEMLER SCIENTIFIC, INC.-6.12%610
MISONIX, INC.11.20%242
DAIKEN MEDICAL CO., LTD.6.54%158
ELECTROCORE, INC.75.64%125
APOLLO ENDOSURGERY, INC.17.06%103